Baseline demographics and disease characteristics
| Characteristics | All participants (n=61) | Camrelizumab (n=19) | Decitabine-plus-camrelizumab (n=42) |
| Median age in years (range) | 27 (12–66) | 28 (18–44) | 26 (12–66) |
| Male | 37 (61%) | 12 (63%) | 25 (60%) |
| Disease stage at initial diagnosis | |||
| Stage II | 13 (21%) | 5 (26%) | 8 (19%) |
| Stage III | 11 (18%) | 3 (16%) | 8 (19%) |
| Stage IV | 37 (61%) | 11 (58%) | 26 (62%) |
| Median time from initial diagnosis to first dose in years (range) | 2 (0.5–12) | 2.8 (0.5–12) | 1.5 (0.5–11) |
| Primary refractory disease* | 32 (52%) | 7 (37%) | 25 (60%) |
| Extranodal disease at enrollment† | 55 (64%) | 12 (63%) | 32 (76%) |
| Median SPD (range) at enrollment (cm2) | 20 (3–102) | 14 (3–96) | 23 (3–102) |
| SPD ≥20 cm2 | 31 (51%) | 7 (37%) | 24 (57%) |
| Number of previous systemic therapy | |||
| Median | 3 | 3 | 3 |
| ≥3 | 45 (74%) | 15 (79%) | 30 (71%) |
| Cycles of previous chemotherapy | |||
| Median (range) | 10 (4–30) | 10 (6–30) | 10 (4–18) |
| ≥10 | 38 (62%) | 12 (63%) | 26 (62%) |
| Previous autologous stem cell transplantation | 17 (28%) | 6 (32%) | 11 (26%) |
| Previous brentuximab vedotin therapy | 2 (3%) | 1 (5%) | 1 (2%) |
Data are n (%), unless specified otherwise.
*Absence of CR or relapse within 90 days of the front-line therapy.
†Sites of extranodal disease were bone, liver, spleen, lung, mediastinal mass, and pleura.
SPD, sum of the products of diameters.